Literature DB >> 28817230

Recent findings on fulminant type 1 diabetes.

Lan Liu1, Ling Zeng1, Dan Sang1, Zeyuan Lu1, Jie Shen2.   

Abstract

Fulminant type 1 diabetes (fT1D) is a new subtype of type 1 diabetes proposed by Imagawa in 2000. It is a clinical syndrome characterized by a markedly rapid and almost complete destruction of pancreatic β cells. Metabolic derangement is more severe in this subtype than in autoimmune type 1 diabetes. The incidence of fT1D is associated with HLA DRB1*04:05DQB1*04:01; both innate and acquired immune disorders might contribute to the development of fT1D. The presence of specific innate immune responses to enterovirus infection connected with enhanced adaptive immune pathways responsible for aggressive β cell toxicity in fT1D. The process of β cell destruction is extremely rapid in fT1D, and the insulin secretary capacity rarely recovers after the onset. The serum glycated albumin to glycated haemoglobin ratio is significantly higher in fT1D; a cut-off value of 3.2 for serum glycated albumin to glycated haemoglobin ratio yielded 97% sensitivity and 98% specificity for differentiating fT1D from type 2 diabetes. Fulminant type 1 diabetes is associated with pregnancy. This article also updates the diagnostic criteria for fT1D by the Japanese Diabetes Association in 2012.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  enteroviruses; fulminant type 1 diabetes; human leukocyte antigen; immunity

Mesh:

Year:  2017        PMID: 28817230     DOI: 10.1002/dmrr.2928

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  7 in total

1.  Clinical study of pregnancy-associated fulminant type 1 diabetes.

Authors:  Lan Liu; Wenjuan Jia; Ruike Liu; Jie Shen
Journal:  Endocrine       Date:  2018-03-02       Impact factor: 3.633

2.  A Pediatric Case of Abrupt-Onset, Autoantibody-Negative Diabetes With Marked Insulin Resistance Concomitant With COVID-19.

Authors:  Alfonso Hoyos-Martinez; Kelly Hicks; Tracy Patel; Jennifer Bell; Yuezhen Lin
Journal:  Clin Diabetes       Date:  2021-07

3.  Impaired glucagon secretion in patients with fulminant type 1 diabetes mellitus.

Authors:  Hisako Komada; Yushi Hirota; Kazuhiko Sakaguchi; Yoko Okuno; Wataru Ogawa; Susumu Seino
Journal:  Endocrine       Date:  2018-09-10       Impact factor: 3.633

4.  A Case of Fulminant Type 1 Diabetes with Gastric and Urinary Retention.

Authors:  Chuan Xing; Wenqian Zhao; Yanjun Wang
Journal:  Diabetes Ther       Date:  2018-11-20       Impact factor: 2.945

5.  Co-Occurrence of Multiple Endocrine Abnormalities Induced by the DIHS/DRESS.

Authors:  Mingqun Deng; Han Wu; Miao Yu; Yi Tian; Yuxiu Li; Xinhua Xiao
Journal:  Int J Endocrinol       Date:  2019-10-03       Impact factor: 3.257

6.  Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus.

Authors:  Lingwen Ying; Xiaojing Ma; Yun Shen; Jingyi Lu; Wei Lu; Wei Zhu; Yufei Wang; Yuqian Bao; Jian Zhou
Journal:  J Diabetes Res       Date:  2020-03-20       Impact factor: 4.011

7.  Integrative Analyses of Genes Associated with Fulminant Type 1 Diabetes.

Authors:  Xiaofeng Ye; Tianshu Zeng; Wen Kong; Lu-Lu Chen
Journal:  J Immunol Res       Date:  2020-10-06       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.